Melanoma: Our Clinical Trials

Clinical trials are research studies that evaluate the safety and effectiveness of new therapies and diagnostic tools, including surgical techniques, chemotherapy drugs, radiation therapy techniques, and vaccines. Clinical trials can also help us compare the effectiveness of prevention strategies or other aspects of your care. If you are eligible to participate in a clinical trial, you may have access to new melanoma therapies that are not yet widely available.

Our treatment team is highly experienced in selecting patients who are most likely to benefit from a particular investigational therapy and can guide you through the process of choosing the most appropriate clinical trial. Learn more about clinical trials.

Here you can find a continually updated listing of Memorial Sloan-Kettering's current clinical trials for melanoma. To learn more about a study, choose from the list below.

Showing 27 trials

Title	Investigator
A Phase I Study of AEB071 in Patients with Metastatic Uveal Melanoma [Protocol 11-167]	Schwartz, Gary, MD
A Phase I Study of an mRNA-Modified Dendritic Cell Vaccine in Patients with Melanoma [Protocol 10-229]	Young, James, MD
A Phase I Study of BMS-986015 with Ipilimumab in Patients with Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Melanoma [Protocol 12-283]	Rizvi, Naiyer, MD
A Phase I Study of Dabrafenib and Ipilimumab with and without Trametinib for Advanced Melanoma [Protocol 12-285]	Wolchok, Jedd, MD, PhD
A Phase I Study of Ipilimumab in Children, Adolescents, and Young Adults with Treatment-Refractory Cancer [Protocol 10-193]	Wexler, Leonard, MD
A Phase I Study of Lirilumab plus Nivolumab in Patients with Advanced Solid Tumors [Protocol 12-224]	Segal, Neil, MD, PhD
A Phase I Study of the NY-ESO-1 Vaccine plus Ipilimumab in Patients with Inoperable or Metastatic Melanoma [Protocol 12-253]	Postow, Michael, MD
A Phase I Study of Vemurafenib in Adolescents with Inoperable Stage IIIC/IV Melanoma with V600 BRAF Mutations [Protocol 11-198]	Pratilas, Christine, MD
A Phase I/IIA Study of Dabrafenib in Children with Advanced BRAF Mutation-Positive Solid Tumors [Protocol 13-016]	Pratilas, Christine, MD
A Phase Ib Study of MDX-1106 (BMS-936558) in Combination with Ipilimumab (BMS-734016) in Patients with Unresectable Stage III or Stage IV Malignant Melanoma [Protocol 09-155]	Wolchok, Jedd, MD, PhD
A Phase II Study of Dabrafenib After Surgery in Patients with BRAF V600 Mutation-Positive Stage IIIC Melanoma [Protocol 12-124]	Chapman, Paul, MD
A Phase II Study of Dasatinib in Patients with Inoperable Locally Advanced or Metastatic c-KIT-Positive Acral or Mucosal Melanoma [Protocol 13-100]	Leitao, Mario, MD
A Phase II Study of Ipilimumab in Children and Adolescents with Stage III/IV Inoperable Melanoma [Protocol 13-043]	Dunkel, Ira, MD
A Phase II Study of Ipilimumab Plus Isolated Limb Infusion with Melphalan and Dactinomycin to Treat Advanced Unresectable Melanoma of the Extremity [Protocol 10-101]	Ariyan, Charlotte, MD
A Phase II Study of LEE011 plus LGX818 in Patients with BRAF-Mutant Melanoma [Protocol 13-097]	Postow, Michael, MD
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma [Protocol 13-102]	Schwartz, Gary, MD
A Phase II Study of LGX818 Given in a Pulsatile Schedule to Patients with Stage III or IV Melanoma with a BRAF Mutation [Protocol 13-053]	Schwartz, Gary, MD
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230)) in Patients with Advanced Uveal Melanoma [Protocol 10-123]	Carvajal, Richard, MD
A Phase II Study of Vorinostat for Metastatic Uveal Melanoma [Protocol 12-027]	Carvajal, Richard, MD
A Phase II Trial of Temozolomide versus AZD6244 in Patients with Metastatic Uveal Melanoma [Protocol 10-053]	Carvajal, Richard, MD
A Phase III Study of BMS-936558 (Nivolumab) versus Standard Chemotherapy in Patients with Advanced Melanoma that Progressed Despite Anti-CTLA-4 Therapy [Protocol 12-254]	D'Angelo, Sandra, MD
A Phase III Study of MEK162 versus Dacarbazine in Patients with Inoperable or Metastatic Melanomas with NRAS Q61 Mutations: The NEMO Trial [Protocol 13-083]	Postow, Michael, MD
A Phase III Study of Nivolumab and Ipilimumab, Together and Individually, in Patients Newly Diagnosed with Advanced Melanoma [Protocol 13-075]	Wolchok, Jedd, MD, PhD
A Phase III Study of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy in Patients with Cutaneous Melanomas that Have Metastasized to the Sentinel Node [Protocol 09-112]	Ariyan, Charlotte, MD
A Phase III Study of Vemurafenib in Patients with Surgically Removed BRAF-Mutant Melanoma Who Have a High Risk of Recurrence [Protocol 12-166]	Chapman, Paul, MD
A Study of the Biologic Effects of BMS-936558 in Patients with Inoperable or Metastatic Melanoma [Protocol 12-231]	Wolchok, Jedd, MD, PhD
An Evaluation of Perceptions and Quality of Life Among Patients Receiving Ipilimumab for Melanoma [Protocol 11-184]	Hay, Jennifer, PhD